- Home
- LPAA vs AARD Comparison
LPAA vs AARD Comparison
Compare LPAA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SELL
N/A
Current Price
$1.17
Company Overview
Basic Information| Metric | LPAA | AARD |
|---|---|---|
| Founded | 2024 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.8M | 97.4M |
| IPO Year | 2024 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LPAA | AARD |
|---|---|---|
| Price | $11.02 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 6.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.47 | $0.93 |
| 52 Week High | $11.67 | $16.60 |
Technical Indicators
Market Signals| Indicator | LPAA | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 66.55 | 25.03 |
| Support Level | $10.61 | $0.93 |
| Resistance Level | $11.19 | $5.88 |
| Average True Range (ATR) | 0.00 | 0.35 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 100.00 | 6.87 |
Price Performance
Historical Comparison LPAA
AARD
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.